PriceTargets.com logo

Adicet Bio - ACET Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.43
  • Forecasted Upside: 98.90 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$13.79 As of 09/26/2022 01:00 AM ET
▼ -0.11 (-0.79%)

This chart shows the closing price for ACET by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adicet Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACET and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACET

Analyst Price Target is $27.43
▲ +98.90% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Adicet Bio in the last 3 months. The average price target is $27.43, with a high forecast of $34.00 and a low forecast of $21.00. The average price target represents a 98.90% upside from the last price of $13.79.

This chart shows the closing price for ACET for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Adicet Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/27/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$23.00Low
8/23/2022Truist FinancialLower Target$27.00Low
6/7/2022JMP SecuritiesReiterated RatingBuy$21.00Medium
3/31/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$28.00Medium
3/17/2022JMP SecuritiesLower TargetMarket Outperform$30.00 ➝ $21.00Medium
3/8/2022Truist FinancialInitiated CoverageBuy$30.00High
3/4/2022Jefferies Financial GroupInitiated CoverageBuy$27.00Low
12/7/2021HC WainwrightReiterated RatingBuy$34.00Low
12/7/2021JMP SecuritiesReiterated RatingBuy$30.00Low
12/6/2021GuggenheimBoost TargetBuy ➝ Buy$22.00 ➝ $32.00High
11/15/2021JMP SecuritiesReiterated RatingBuy$30.00Medium
8/24/2021JonestradingReiterated RatingBuy$33.00Low
5/17/2021BTIG ResearchInitiated CoverageBuy$34.00N/A
5/5/2021JonestradingInitiated CoverageBuy$33.00N/A
4/29/2021HC WainwrightInitiated CoverageBuy$27.00N/A
4/29/2021JonestradingInitiated CoverageBuy$33.00N/A
4/23/2021HC WainwrightInitiated CoverageBuy$27.00N/A
4/14/2021GuggenheimInitiated CoverageBuy$22.00N/A
4/8/2021GuggenheimInitiated CoverageBuy$22.00N/A
11/4/2020B. RileyInitiated CoverageBuy$30.00N/A
10/27/2020JMP SecuritiesInitiated CoverageOutperform$30.00N/A
10/16/2020B. RileyReiterated RatingBuyN/A
10/16/2020First AnalysisDowngradeHoldN/A
10/15/2020WedbushInitiated CoverageNeutral ➝ Outperform$25.00N/A
4/19/2018Craig HallumDowngradeHold ➝ SellHigh
(Data available from 9/26/2017 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/28/2022
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/29/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/29/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/27/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Adicet Bio logo
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Read More

Today's Range

Now: $13.79
Low: $13.69
High: $14.44

50 Day Range

MA: $15.74
Low: $13.64
High: $18.74

52 Week Range

Now: $13.79
Low: $7.13
High: $21.17

Volume

513,636 shs

Average Volume

491,997 shs

Market Capitalization

$552.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Adicet Bio?

The following Wall Street research analysts have issued reports on Adicet Bio in the last year: Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., StockNews.com, Sumitomo Mitsui Financial Group, Inc., TheStreet, and Truist Financial Co..
View the latest analyst ratings for ACET.

What is the current price target for Adicet Bio?

7 Wall Street analysts have set twelve-month price targets for Adicet Bio in the last year. Their average twelve-month price target is $27.43, suggesting a possible upside of 96.9%. HC Wainwright has the highest price target set, predicting ACET will reach $34.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $21.00 for Adicet Bio in the next year.
View the latest price targets for ACET.

What is the current consensus analyst rating for Adicet Bio?

Adicet Bio currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACET will outperform the market and that investors should add to their positions of Adicet Bio.
View the latest ratings for ACET.

What other companies compete with Adicet Bio?

Other companies that are similar to Adicet Bio include Collegium Pharmaceutical, Janux Therapeutics, ANI Pharmaceuticals, Phibro Animal Health and GH Research. Learn More about companies similar to Adicet Bio.

How do I contact Adicet Bio's investor relations team?

Adicet Bio's physical mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company's listed phone number is (857) 315-5528 and its investor relations email address is [email protected] The official website for Adicet Bio is www.aceto.com. Learn More about contacing Adicet Bio investor relations.